Fulcrum Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$333.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Fulcrum Therapeutics's estimated annual revenue is currently $22M per year.(i)
  • Fulcrum Therapeutics received $80.0M in venture funding in September 2018.
  • Fulcrum Therapeutics's estimated revenue per employee is $155,000
  • Fulcrum Therapeutics's total funding is $333.5M.

Employee Data

  • Fulcrum Therapeutics has 142 Employees.(i)
  • Fulcrum Therapeutics grew their employee count by 28% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

What if we could regulate genes, not just discover them What if we could treat disease at their genetic source What if we could integrate multiple disciplines to develop breakthrough medicines What if you could be a part of a passionate team committed to the patients we serve We can. We will. We Are. Join Us. We are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. A fulcrum is defined as the point on which a lever rests, balances and pivots. Fulcrum Therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. The Fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. Our Approach The sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome gene regulation. The Fulcrum product engine is based on the breakthrough biology of gene regulation. It will bring to bear medicines for devastating diseases across multiple therapeutic areas by modulating or balancing the expression of the genes known to drive disease. By focusing on disease causative genes, we are taking a highly personalized approach to treating disease unlocking the druggable mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies.

keywords:N/A

$333.5M

Total Funding

142

Number of Employees

$22M

Revenue (est)

28%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Fulcrum Therapeutics News

2021-06-21 - FULCRUM THERAPEUTICS, INC. Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC)

CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced multiple presentations at the 28th Annual FSHD Society Inte ...

2021-06-22 - Fulcrum Therapeutics : Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced multiple presentations at the 28th Annual FSHD Society International Research Congress (IRC). June 24, 2021 IR ...

2021-08-12 - Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 6,600 ...

09/04/2019 - Fulcrum Therapeutics Appoints Pamela Strode, Seasoned ...

Fulcrum Therapeutics Appoints Pamela Strode, Seasoned Industry Executive, to Lead Regulatory Affairs Team ...

09/03/2019 - Fulcrum Therapeutics to Present at the Morgan Stanley 17th ...

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical ...

08/19/2019 - Fulcrum Therapeutics Announces Initiation of ReDUX4, a ...

CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$25.5M1426%N/A
#2
$45.3M1422%N/A
#3
$22.6M1426%N/A
#4
$20M14314%$119.7M
#5
$33.3M1443%N/A

Fulcrum Therapeutics Funding

DateAmountRoundLead InvestorsReference
2016-07-20$55.0MAThird Rock VenturesArticle
2017-05-11$UndisclosedAGoogle VenturesArticle
2018-09-06$80.0MBForesite CapitalArticle